Literature DB >> 16513441

Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.

Eric P Brass1, Roger J Lewis, Raymond Lipicky, James Murphy, William R Hiatt.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16513441     DOI: 10.1016/j.clpt.2005.11.012

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

1.  The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes.

Authors:  Eric P Brass
Journal:  Diabetes Spectr       Date:  2014-05

Review 2.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; J-P Valentin; P Sager; K Thomas
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

4.  International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; A Breidenbach; K Bruse; H S Feldman; D Garnes; T Hammond; W Haverkamp; C January; J Koerner; C Lawrence; D Leishman; D Roden; J P Valentin; M A Vos; Y-Y Zhou; T Karluss; P Sager
Journal:  Br J Pharmacol       Date:  2008-08       Impact factor: 8.739

5.  Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.

Authors:  Sumeet Subherwal; Kevin J Anstrom; William S Jones; Michael G Felker; Sanjay Misra; Michael S Conte; William R Hiatt; Manesh R Patel
Journal:  Am Heart J       Date:  2012-09       Impact factor: 4.749

Review 6.  Leveraging Machine Learning and Artificial Intelligence to Improve Peripheral Artery Disease Detection, Treatment, and Outcomes.

Authors:  Alyssa M Flores; Falen Demsas; Nicholas J Leeper; Elsie Gyang Ross
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.